Disruptive Technologies Targeting Drug Resistance

Most drugs for cancer and infectious diseases target proteins, which mutate and down-regulate.

We take a different approach. Our lead biotherapeutic, VTRU200, targets aberrant and abundant sugar and lipid signatures on viruses and cancers that do not exist on normal cells, are not encoded by mRNA, and do not change.